Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07585695

Coronary Artery Disease Screening in Patients With Chronic Kidney Disease

Patients with chronic kidney disease (CKD) have a markedly increased cardiovascular risk, with coronary artery disease being a leading cause of morbidity and mortality. Conventional cardiovascular risk scores and non-invasive diagnostic tests have limited accuracy in this population, partly due to atypical symptoms and frequent structural heart disease. Coronary flow reserve (CFR) is a key marker of coronary microvascular dysfunction and has strong prognostic value, but its assessment is usually limited to invasive techniques. Recent advances in cadmium-zinc-telluride single-photon emission computed tomography (CZT-SPECT) allow non-invasive measurement of CFR. The EVACKD study aims to evaluate the prognostic value of CFR assessed by CZT-SPECT in patients with CKD for predicting major adverse cardiovascular events over a 2-year follow-up.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Kidney Disease (CKD) Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Chronic Disease Coronary Artery Disease Coronary Artery Disease (CAD) Coronary Disease Disease Attributes Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Heart Diseases Kidney Diseases Male Urogenital Diseases Myocardial Ischemia Pathologic Processes Pathological Conditions, Signs and Symptoms Renal Insufficiency Renal Insufficiency, Chronic Urogenital Diseases Urologic Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female patients aged over 18 years
  • Affiliated with the French social security system
  • Patients at renal risk based on albuminuria (Alb) and glomerular filtration rate (GFR < 30 mL/min/1.73 m², or GFR < 45 mL/min/1.73 m² with albuminuria > 30 mg/g, or GFR < 60 mL/min/1.73 m² with albuminuria > 300 mg/g)
  • Patients undergoing, independently of the research and according to the clinician's decision as part of standard care, CZT-SPECT myocardial perfusion imaging with coronary flow reserve measurement for cardiovascular risk assessment
  • Having expressed no objection to participation in this study

Exclusion criteria

  • Legally protected adult (Article L1121-8 of the French Public Health Code)
  • Person deprived of liberty (Article L1121-8 of the French Public Health Code)
  • Pregnant woman
  • Patient who has undergone a normal coronary exploration within the past year

Treatment and study plan

Primary outcomes

  1. To assess the prognostic value of impaired coronary flow reserve measured by CZT myocardial perfusion imaging

    Time frame: 2-year follow-up

    Composite endpoint including cardiac mortality, non-fatal myocardial infarction, non-fatal ischemic stroke, and hospitalization for heart failure.

Secondary outcomes

  1. To assess the prognostic value of coronary flow reserve to each individual component of the primary endpoint

    Time frame: 2 years

    To evaluate each component separately : Cardiac mortality rate, non-fatal myocardial infarction rate, non-fatal ischemic stroke rate, hospitalization rate for heart failure, and all-cause mortality rate.

  2. To assess the prognostic value of coronary flow reserve for Major Adverse Kidney Events (MAKE)

    Time frame: At 1-year and 2-year follow-up

    Rate of patients with Major Adverse Kidney Events (MAKE), defined by the composite endpoint of death, dependence on renal replacement therapy, and a ≥50% decline in estimated glomerular filtration rate (eGFR) from baseline

  3. To assess the number of Acute Kidney Injury (AKI) events during follow-up

    Time frame: 2 years

    Evaluation of the Acute Kidney Injury (AKI) rate classified into three grades: Grade 1 (1.5- to 2-fold increase in serum creatinine), Grade 2 (2- to 3-fold increase), and Grade 3 (>3-fold increase or need for dialysis)

  4. To assess the number of coronary revascularizations by coronary artery bypass grafting or percutaneous coronary intervention

    Time frame: 2 years

    Performed by calculating the rate of revascularization by coronary artery bypass grafting or percutaneous coronary intervention

  5. To assess the prevalence of ischemic heart disease without significant coronary artery stenosis (INOCA)

    Time frame: 2 years

    Rate of ischemic heart disease without significant coronary artery stenosis (INOCA)

Study contacts

Contact information is provided by the study sponsor or research team.

Clémence Charlon

CONTACT

[email protected]

+33476766652

Gilles Barone Rochette

CONTACT

[email protected]

+33476765172

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Screening for Coronary Artery Disease in Patients With Chronic Kidney Disease

Acronym: EVACKD

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 14, 2026
Registry last updated
May 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.